1. 2023
  2. 2022
  3. Amelioration of endothelial dysfunction by sodium glucose co-transporter 2 inhibitors: pieces of the puzzle explaining their cardiovascular protection

    Li, X., Preckel, B., Hermanides, J., Hollmann, M. W., Zuurbier, C. J. & Weber, N. C., Aug 2022, In: British journal of pharmacology. 179, 16, p. 4047-4062 16 p.

    Research output: Contribution to journalReview articleAcademicpeer-review

  4. Empagliflozin reduces oxidative stress through inhibition of the novel inflammation/NHE/[Na+]c/ROS-pathway in human endothelial cells

    Uthman, L., Li, X., Baartscheer, A., Schumacher, C. A., Baumgart, P., Hermanides, J., Preckel, B., Hollmann, M. W., Coronel, R., Zuurbier, C. J. & Weber, N. C., Feb 2022, In: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 146, 112515.

    Research output: Contribution to journalArticleAcademicpeer-review

  5. 2021
  6. Effects of hyperglycemia and diabetes mellitus on coagulation and hemostasis

    Li, X., Weber, N. C., Cohn, D. M., Hollmann, M. W., Devries, J. H., Hermanides, J. & Preckel, B., 1 Jun 2021, In: Journal of clinical medicine. 10, 11, 2419.

    Research output: Contribution to journalArticleAcademicpeer-review

  7. Sodium glucose co-transporter 2 inhibitors ameliorate endothelium barrier dysfunction induced by cyclic stretch through inhibition of reactive oxygen species

    Li, X., Römer, G., Kerindongo, R. P., Hermanides, J., Albrecht, M., Hollmann, M. W., Zuurbier, C. J., Preckel, B. & Weber, N. C., 1 Jun 2021, In: International journal of molecular sciences. 22, 11, 6044.

    Research output: Contribution to journalArticleAcademicpeer-review

ID: 7059161